Biotest AG
↗Dreieich, Germany
Biotest AG is a global specialist in plasma protein therapeutics and biopharmaceutical drugs, headquartered in Dreieich, Germany. Founded in 1946, the company develops, manufactures, and markets biological medicinal products derived from human blood plasma for treating diseases in clinical immunology, hematology, and intensive care medicine. With 2,495 employees as of 2024, Biotest operates 40 plasma collection centers across Europe and maintains manufacturing capabilities exclusively in Germany. The company was acquired by Grifols, S.A. in May 2022 and is now a subsidiary of the Barcelona-based global healthcare leader. Biotest specializes in immunoglobulin therapies, clotting factors, albumin-based products, and next-generation plasma protein therapeutics targeting life-threatening disorders. Recent FDA approval of Yimmugo (immune globulin, human-dira) and positive Phase III results for fibrinogen concentrate (FESILTY) represent significant pipeline achievements positioning Biotest for substantial growth in the US market.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Immunology and Hematology Therapies
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$726M (2024)
Founded:1946
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 3 / FDA Approved
Modalities:Plasma-derived proteins, Immunoglobulins, Clotting factors, Albumin, Monoclonal antibodies
Active Trials:2
Trial Phases:Phase 3: 2
FDA Approvals:2
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Grifols, S.A.
Acquired By:Grifols, S.A. (2022-05-01)
Subsidiaries:Biotest Pharma GmbH, Plasma Service Europe GmbH
Key Partnerships:Kedrion Biopharma: Exclusive US distribution agreement for Yimmugo and BIVIGAM immunoglobulins, ImmunoGen, Inc.: Development collaboration on immunoconjugate technology, UCSF: Clinical trial partnership for trimodulin in severe community-acquired pneumonia
COMPETITION
Position:Leader
Competitors:CSL Limited (Australia), Takeda Pharmaceutical (Japan), Grifols, S.A. (Spain/parent company), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), ADMA Biologics (US), Baxter International +2 more
LEADERSHIP
Key Executives:
Dr. Jörg Schüttrumpf - CEO
Martin Möller - Chief Financial Officer (CFO)
Prof Dr Gernot Hebestreit - Supervisory Board Chairman (elected 2024)
Scientific Founders:Carl Adolf Schleussner, Hans Schleussner
Board Members:Prof Dr Gernot Hebestreit (Chairman of Supervisory Board and Audit Committee)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Biotest AG. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.